Cyprotex Discovery Receives French Research Tax Credit Accreditation
MACCLESFIELD, England, April 21, 2010 /PRNewswire/ -- Cyprotex (AIM:CRX), the drug discovery technology and
information company, is pleased to announce that it has received French
research tax credit approval for years 2009 through to 2011.
The French Ministry of Research (Ministère de l'Enseignement
Supérieur et de la Recherche) has granted the French R? tax credit ("Crédit
d'Impôt Recherche", CIR) accreditation to Cyprotex as of March 2010. This
initiative allows eligible French pharmaceutical, biotech and agricultural
companies subject to corporate tax in France, the ability to claim
significant tax relief on costs generated in R? requirements that are
outsourced to Cyprotex Discovery.
Dr Anthony Baxter, Cyprotex's Chief Executive Officer,
comments: 'We are delighted to receive this recognition and approval from the
French Ministry of Research which will provide greater opportunities to
support our current client base and allow for improved collaborations with
future French clients.'
Additional information on the French research tax credit system is
available from the Ministère de l'Enseignement Supérieur et de la Recherche
site - http://www.enseignementsup-recherche.gouv.fr/
For further information:
Cyprotex PLC
Dr. Anthony Baxter, Chief Executive Officer
Tel: +44-1625-505-100
a.baxter@cyprotex.com
http://www.cyprotex.com
Execution Noble & Company Limited
John Llewellyn-Lloyd
Sam Reynolds
Tel:+44(0)20-7456-9191
Public Relations
Financial Dynamics
Ben Brewerton
Ben Atwell
Mo Noonan
Tel: +44(0)20-7831-3113
For further information: Cyprotex PLC, Dr. Anthony Baxter, Chief Executive Officer, Tel: +44-1625-505-100, a.baxter@cyprotex.com, http://www.cyprotex.com; Execution Noble & Company Limited, John Llewellyn-Lloyd, Sam Reynolds, Tel:+44(0)20-7456-9191; Public Relations, Financial Dynamics, Ben Brewerton, Ben Atwell, Mo Noonan, Tel: +44(0)20-7831-3113